MFC — Manulife Financial Corporation

Summary of Manulife Financial Corporation Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Core Earnings Growth: Manulife reported record core earnings with an 8% growth in core EPS year-over-year, reaching $1.5 billion in net income for the quarter.
• New Business CSM Growth: New business CSM growth exceeded 20% across all insurance segments, contributing to a double-digit increase in the CSM balance.
• Remittances and Capital Return: Generated $6.4 billion in remittances, exceeding the $6 billion target, and returned nearly $5.5 billion to shareholders through dividends and share buybacks.
• LICAT Ratio: Maintained a strong LICAT ratio of 136% and a leverage ratio of 23.9%.
• Dividend Increase: Announced a 10% increase in the quarterly common share dividend.

2. Strategic Updates and Business Highlights

• Refreshed Strategy: Introduced a new enterprise strategy aimed at becoming the #1 choice for customers, focusing on high-quality sustainable growth and innovation.
• Acquisitions: Acquired Comvest Credit Partners and announced a joint venture in India and an acquisition in Indonesia, enhancing the company’s portfolio.
• AI Initiatives: Ranked first among global life insurers for AI maturity, with ongoing investments in AI to improve efficiency and customer engagement.
• Health Partnerships: Collaborated with Bupa International in Hong Kong and introduced innovative health solutions in Canada and the U.S.

3. Forward Guidance and Outlook

• 2027 Targets: Confident in achieving core ROE targets of 18% and above by 2027, despite current headwinds in the U.S. segment.
• Growth Expectations: Anticipate continued growth in Asia, particularly in the insurance sector, and expect recovery in U.S. mortality experience to stabilize.

4. Bad News, Challenges, or Points of Concern

• Net Outflows: Experienced net outflows of $9.5 billion in Global WAM due to large retirement plan redemptions and pressures in the North American retail business.
• U.S. Mortality Experience: Ongoing unfavorable mortality claims experience, particularly in the U.S. segment, has raised concerns about long-term profitability.
• Regulatory Pressures: Sales in Hong Kong were impacted by regulatory changes affecting the broker channel, leading to variability in sales performance.
• Investment Performance: Reported a $232 million charge in the ALDA portfolio due to lower-than-expected returns from infrastructure, private equity, and real estate.

5. Notable Q&A Insights

• Hong Kong Sales: Management expressed confidence that sales would recover as brokers adjust to regulatory changes, despite recent declines.
• U.S. Segment Variability: Management reassured that recent mortality experience is viewed as normal variability rather than a long-term trend, with expectations for stabilization.
• Capital Management: Discussed the balance between share buybacks and organic investments, with a commitment to completing the new NCIB program.
• Private Equity Concerns: Addressed investor concerns regarding private equity and private debt, emphasizing strong performance and management of risk within the portfolio.

Overall, Manulife demonstrated strong financial results and strategic initiatives in 2025, while also navigating challenges in specific segments and market conditions. The company remains focused on achieving its long-term targets and enhancing shareholder value.